← Library

This white paper discusses studies investigating predictive biomarkers for clinical response to immunotherapies targeting PD-1/PD-L1 and the use of biomarkers identified in preclinical studies to accelerate development of small molecule inhibitors of the fibroblast growth factor (FGF)/FGF receptor (FGFR). The potential of next generation sequencing (NGS) for predicting tumor neo-antigens that can be targeted using immunotherapy is also explored.